Computer models to improve combination treatments for diffuse large B‑cell lymphoma
Modeling and analysis of curative combination therapy for Diffuse Large B-Cell Lymphoma
This project builds computer simulations to help design better combination drug regimens for people with diffuse large B‑cell lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11260268 on NIH RePORTER |
What this research studies
Researchers will create computer simulations that combine data from past clinical trials, drug dosing, and tumor behavior to mimic how DLBCL responds to multi‑drug treatment. The models will include differences between patients and differences inside each tumor, plus drug interactions, schedules, and side‑effect tolerability. They will test the simulations by comparing their predictions to results from earlier trials and use successful models to suggest new combination regimens. The goal is to guide future clinical trials toward more curative and less toxic therapy options for patients.
Who could benefit from this research
Good fit: People diagnosed with diffuse large B‑cell lymphoma, especially those interested in or enrolled in combination therapy clinical trials, are the most relevant group.
Not a fit: Patients with other cancer types or non‑cancer conditions are unlikely to receive direct benefit from this DLBCL‑focused modeling work.
Why it matters
Potential benefit: If successful, this could help design combination therapies that increase cure rates and reduce harmful side effects for people with DLBCL.
How similar studies have performed: Related modeling approaches have previously predicted outcomes in several solid‑tumor trials and aided drug approvals, but applying these methods to curative DLBCL regimens with intra‑tumor heterogeneity is newer and less tested.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Palmer, Adam Christopher — Univ of North Carolina Chapel Hill
- Study coordinator: Palmer, Adam Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.